![](/images/graphics-bg.png)
Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease
Joint Authors
Han, Tianzhao
Rong, Gong
Quan, Dayong
Shu, Ying
Liang, Zhu
She, Ninglan
Liu, Manli
Yang, Bing
Cheng, Gong
Lv, Yongman
Stern, Leonard
Source
Issue
Vol. 2013, Issue 2013 (31 Dec. 2013), pp.1-11, 11 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-12-27
Country of Publication
Egypt
No. of Pages
11
Main Subjects
Abstract EN
Previous studies have demonstrated the safety and efficacy of using Paricalcitol for the treatment of secondary hyperparathyroidism (SHPT) in patients on dialysis.
The aim of the current meta-analysis was to assess the safety and efficacy of Paricalcitol for the management of SHPT in patients with chronic kidney disease (CKD) not yet on dialysis.
A secondary aim was to determine if sufficient data was available to assess the effect of Paricalcitol for the management of proteinuria.
Methods.
A meta-analysis was conducted using the Cochrane Collaboration’s RevMan 4.2 software.
Results.
Paricalcitol is effective in lowering PTH in patients with CKD not yet on dialysis and is also effective in lowering proteinuria in diabetic CKD patients.
However, we uncovered a safety signal identifying an elevated calcium phosphate product and a trend towards the development of hypercalcemia.
A phosphate elevation was not demonstrated because the target used in the clinical studies was a P>5.5 mg/dl, a value appropriate for dialysis patients and not CKD patients.
Conclusion.
Although Paricalcitol is effective in lowering PTH, we advise caution in the use of any active Vitamin D analogues in patients with CKD because of the potential risk of exacerbating vascular calcification.
American Psychological Association (APA)
Han, Tianzhao& Rong, Gong& Quan, Dayong& Shu, Ying& Liang, Zhu& She, Ninglan…[et al.]. 2012. Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease. BioMed Research International،Vol. 2013, no. 2013, pp.1-11.
https://search.emarefa.net/detail/BIM-1004019
Modern Language Association (MLA)
Han, Tianzhao…[et al.]. Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease. BioMed Research International No. 2013 (2013), pp.1-11.
https://search.emarefa.net/detail/BIM-1004019
American Medical Association (AMA)
Han, Tianzhao& Rong, Gong& Quan, Dayong& Shu, Ying& Liang, Zhu& She, Ninglan…[et al.]. Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease. BioMed Research International. 2012. Vol. 2013, no. 2013, pp.1-11.
https://search.emarefa.net/detail/BIM-1004019
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1004019